The Charles River Corporate Development Department employs mergers, acquisitions, and licensing agreements in an effort to continually expand our products and services portfolio and better meet your evolving needs. Specifically, we focus on strategic, bolt-on acquisitions that help enhance our core business and geographic footprint.
In the past, Charles River has acquired companies or formed joint ventures focused on preclinical contract research services, Phase I clinical services, endotoxin testing, and most recently biopharmaceutical services (BPS). Our acquisitions have included facilities in the United States, Scotland, Canada, Germany, and China.
We also seek licensing agreements that serve to enhance our research models business as well as our larger portfolio of services. In targeting these new technologies, we focus on the needs of our existing customer base within the pharmaceutical and biotechnology industries so we can help them accelerate their research and drug development.
For more information about merger and acquisition opportunities, please contact acquisitions@crl.com. To provide preliminary information regarding technologies available for licensing, please contact licensing@crl.com.
Mouse Model Licensing Opportunities
We are currently actively seeking to in-license mouse models within the following disease areas:
- Oncology
- Metabolism and Diabetes
- Cardiovascular
- Inflammation and Arthritis
Specifically, we are looking for published models with well-developed phenotypes that are fully characterized and validated in areas of active research and drug development covered by solid intellectual property. We strongly prefer exclusive licensing opportunities, but will consider nonexclusive opportunities in some cases.
Please contact us at licensing@crl.com for more information.